Trial May Have Identified Biomarkers For Men With Metastatic Castration-Resistant Prostate Cancer Who Respond Well To Ipilimumab
May 13, 2020
Healio (5/12, Byrne) reports on a phase 2 trial in which “researchers identified common biomarkers among men with metastatic castration-resistant prostate cancer who responded favorably to the CTLA-4 inhibitor ipilimumab.” Lead author Sumit K. Subudhi, MD...